The results of the phase III ClarIDHy trial have led to US FDA approval of ivosidenib as a therapeutic option for patients with locally advanced or metastatic cholangiocarcinoma (CCA) harboring isocitrate dehydrogenase 1 (IDH1) mutations.
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis / Rimini, Margherita; Burgio, Valentina; Antonuzzo, Lorenzo; Rimassa, Lorenza; Oneda, Ester; Lavacchi, Daniele; Personeni, Nicola; Ratti, Francesca; Pedica, Federica; Della Corte, Angelo; Persano, Mara; De Cobelli, Francesco; Aldrighetti, Luca; Scartozzi, Mario; Cascinu, Stefano; Casadei-Gardini, Andrea. - In: TARGETED ONCOLOGY. - ISSN 1776-2596. - 17:5(2022), pp. 591-596. [10.1007/s11523-022-00917-7]
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis
Rimini, Margherita;Ratti, Francesca;Pedica, Federica;Della Corte, Angelo;De Cobelli, Francesco;Aldrighetti, Luca;Cascinu, Stefano;Casadei-Gardini, Andrea
2022-01-01
Abstract
The results of the phase III ClarIDHy trial have led to US FDA approval of ivosidenib as a therapeutic option for patients with locally advanced or metastatic cholangiocarcinoma (CCA) harboring isocitrate dehydrogenase 1 (IDH1) mutations.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
